Clinical Trial

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

Study acronym: HyPeR
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
HyPeR is a multi-centre Phase 1 Dose Escalation Study of Guadecitabine (SGI-110)/ASTX727 a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours. The investigators will be investigating the safety and toxicity of the combination.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2016-12-16; most recent amendment 2026-05-07.
Status change: Recruiting → Active, Not Recruiting 2026-05-07
Status change: Active, Not Recruiting → Recruiting 2024-03-19
Status change: Recruiting → Active, Not Recruiting 2020-01-21
Status change: Not Yet Recruiting → Recruiting 2018-10-17
Trial Details
NCT Number NCT02998567
Lead Sponsor Royal Marsden NHS Foundation Trust
Collaborators: Astex Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Institute of Cancer Research, United Kingdom
Conditions Non Small Cell Lung Cancer
Enrollment 60 participants
Start Date 2017-01-26
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-12